Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies

NCT07110194 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

CD20-positive Hematological Malignancies

Interventions

DRUG: TQB2825 Injection (Subcutaneous Injection)

Sponsor

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.